Cantor Fitzgerald Starts Ligand Pharma (LGND) at Buy; Fundamentally Undervalued; Building Momentum In 2012

Article Stock Quotes (1) Comments (0)

Cantor Fitzgerald initiates coverage on Ligand Pharma (NASDAQ: LGND) with a Buy. PT $19.00.

Analyst, Irina Rivkind, said, "Ligand's shareholders have suffered through years of weak performance since 2007. We think the story warrants a new look since the company acquired Cydex and its CAPTISOL drug formulation technology and is also poised for a significant influx in royalties from label expansion of GSK's Promacta into Hepatitis C (HCV) and the eventual approval of Onyx's carfilzomib in multiple myeloma."

For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.

Shares of Ligand Pharma closed at $12.38 yesterday, with a 52 week range of $9.76-$18.74.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Michael Kors (KORS) Under-Appreciated; Canaccord Genuity Starts at Buy
• FBR Capital Starts Taylor Morrison Home (TMHC) at Outperform; Emerging Premier Homebuilder
• Gabelli Starts Abbott Labs (ABT) at Buy

Create E-mail Alert Related Categories

New Coverage

Related Entities

Cantor Fitzgerald

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?